Evidence map›Paper›PMID 20086085›Full record

ArticleInfection and immunity2010

Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans.

David R Tribble, Shahida Baqar, Daniel A Scott, Michael L Oplinger, Fernando Trespalacios, David Rollins, Richard I Walker, John D Clements, Steven Walz, Paul Gibbs and 4 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Infection and immunity, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02280044 (Double Blind, Placebo-Controlled Trial Assessing the Efficacy of Rifaximin in Preventing Campylobacteriosis in Subjects Challenged With Campylobacter Jejuni), which is not on this map. Cited by 49 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
8.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02280044 phase2 / phase3completednot on this mapstarted 2014, after this paper: background citation

Double Blind, Placebo-Controlled Trial Assessing the Efficacy of Rifaximin in Preventing Campylobacteriosis in Subjects Challenged With Campylobacter Jejuni

TypeinterventionalSponsorJohns Hopkins Bloomberg School of Public HealthRan2014 to 2016Enrolled30ConditionsDysentery, Diarrhea, Enteric CampylobacteriosisArmsRifaximin intervention, Placebo intervention
3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 1 synthesis or guideline pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Lack of homologous protection against Campylobacter jejuni CG8421 in a human challenge model.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2013
    Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. The Transmission ofPathogens (Basel, Switzerland) · 2024
    Article
  10. Article
  11. Article
  12. Campylobacter in Africa - A specific viewpoint.European journal of microbiology & immunology · 2023
    Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Innate Lymphoid Cells in Response to Intracellular Pathogens: ProtectionFrontiers in cellular and infection microbiology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

David R TribbleNaval Medical Research Center, Silver Spring, Maryland, USA. dtribble@usuhs.mil
Shahida Baqar
Daniel A Scott
Michael L Oplinger
Fernando Trespalacios
David Rollins
Richard I Walker
John D Clements
Steven Walz
Paul Gibbs
Edward F Burg
Anthony P Moran
Lisa Applebee
A Louis Bourgeois
Naval Medical Research Command · USUnited States Department of the Army · USOllscoil na Gaillimhe – University of Galway · IETulane University · USUnited States Army Medical Research Institute of Infectious Diseases · USUS Biologic (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A human Campylobacter jejuni infection model provided controlled exposure to assess vaccine efficacy and investigate protective immunity for this important diarrheal pathogen. A well-characterized outbreak strain, C. jejuni 81-176, was investigated using a volunteer experimental infection model to evaluate the dose range and duration of protection. Healthy Campylobacter-seronegative adults received C. jejuni strain 81-176 via oral inoculation of 10(5), 10(7), or 10(9) CFU (5 adults/dose), which was followed by clinical and immunological monitoring. Based on dose range clinical outcomes, the 10(9)-CFU dose (n = 31) was used to assess homologous protection at 28 to 49 days (short-term veterans [STV]; n = 8) or 1 year (long-term veterans [LTV]; n = 7) after primary infection. An illness dose effect was observed for naïve subjects (with lower doses, 40 to 60% of the subjects were ill; with the 10(9)-CFU dose, 92% of the subjects were ill) along with complete protection for the STV group and attenuated illness for the LTV group (57%). Partial resistance to colonization was seen in STV (25% of the subjects were not infected; 3-log-lower maximum excretion level). Systemic and mucosal immune responses were robust in naïve subjects irrespective of the dose or the severity of illness. In contrast, in STV there was a lack of circulating antibody-secreting cells (ASC), reflecting the local mucosal effector responses. LTV exhibited comparable ASC responses to primary infection, and anamnestic fecal IgA responses likely contributed to self-resolving illness prior to antibiotic treatment. Campylobacter antigen-dependent production of gamma interferon by peripheral blood mononuclear cells was strongly associated with protection from illness, supporting the hypothesis that TH1 polarization has a primary role in acquired immunity to C. jejuni. This study revealed a C. jejuni dose-related increase in campylobacteriosis rates, evidence of complete short-term protection that waned with time, and immune response patterns associated with protection.

Indexed as

Administration, OralAdultAntibodies, BacterialBacterial VaccinesCampylobacter InfectionsCampylobacter jejuniDiarrheaFecesFemaleHuman ExperimentationHumansImmunity, MucosalImmunoglobulin AImmunologic MemoryInterferon-gammaLeukocytes, MononuclearAntibodies, BacterialBacterial VaccinesImmunoglobulin AInterferon-gamma

Identifiers

PMID20086085
PMCPMC2849408
OpenAlexW2125509757

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.